News and Trends 5 Jul 2017 Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib’s clinical pipeline. Galapagos and Gilead clearly have big expectations for filgotinib. The small molecule is already in Phase III for rheumatoid arthritis, Crohn’s disease and ulcerative colitis. The team is now launching a new Phase II trial in […] July 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2017 Cutting Through the BS in Biopharma: How To Spot Hype Faced with the oft-quoted figure that 90% of clinical trials end in failure, how can patients, investors, and readers be spared more disappointment? After discussing failures in biotech at Refresh earlier in June, I headed to Copenhagen last week for the European Conference for Science Journalists to cajole a panel into discussing how some of these stories feature […] July 5, 2017 - 4 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Jul 2017 British Liquid Biopsy for Ovarian Cancer Outperforms the Gold Standard The British company Angle has announced results from a large-scale trial that seem to indicate its liquid biopsy technology could surpass the gold standard in ovarian cancer diagnosis. Angle, in the UK, is developing liquid biopsy tests to replace biopsies in the diagnosis of cancer. The company has announced results from a 400-patient trial in […] July 4, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 From Rockets to DNA – From SpaceX to CRISPR With CRISPR being one of the most significant discoveries in genome engineering history, many scientists are now turning towards it as a basic foundation of their research. In response, companies are developing new technologies and products designed to help these very scientists become more effective in their research. One such company is Silicon Valley entity […] July 3, 2017 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Jul 2017 Scottish AI Biotech Recruits Another Pharma Partner in €37M Deal After Sanofi recruited Exscientia in a €250M deal last May, GSK has taken an interest in the startup and invested in a collaboration of its own. Artificial intelligence has been carving out a niche for itself in biotech, and Exscientia is fast establishing itself as a key player in the field. In May, the company signed a […] July 3, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2017 Quantum Worms from London win the Biodesign Challenge 2017 A team of students from Central Saint Martins, London, has won this year’s biodesign challenge with a project in which worms turn into tech factories. Every year, teams working at the intersection of biology and design compete to win the Biodesign Challenge held at the famous New York City’s Museum of Modern Art (MoMA). This year’s edition […] July 1, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy based on off-the-shelf mRNA technology. eTheRNA is one of the few companies working in mRNA therapies that are running clinical trials. The Belgian biotech has announced the start of a Phase Ib trial with its candidate TriMix-MEL, also called ECI-006, in patients […] June 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jun 2017 €40M in Series C for a British Biotech Treating Blindness with Gene Therapy NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […] June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2017 Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to enter the promising CAR-T field in 2015, when it acquired the rights to UCART19 from Cellectis. The therapy, currently in Phase I, has already saved two babies […] June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2017 This French Biotech is Starting Two New Trials to Treat Kidney and Liver Fibrosis Genkyotex has announced a new Phase II trial in diabetic kidney disease and patient enrolment in another Phase II study for PBC. Genkyotex is not giving up after its lead candidate, GKT831, failed to meet the primary endpoint in a Phase II trial in patients with type 2 diabetes and kidney disease. The French biotech has […] June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2017 New Drug for Neuropathic Pain Is Forging its Way through the Clinic Pharmaleads has scored positive results in a first Phase I trial for its DENKI peptide PL265 to treat chronic neuropathic pain. The treatment of neuropathic pain commonly involves the prescription of opioids, anti-depressants or anti-convulsants, despite limited efficacy and marked side-effects of these drugs. Paris-based Pharmaleads is exploring new pathways to treat pain based on so-called DENKI peptides […] June 29, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jun 2017 Swiss Scientists Have Designed New Proteins to Treat Muscular Dystrophy Researchers at the University of Basel have designed two proteins that can reverse congenital muscular dystrophy and increase the lifespan of mice. Congenital muscular dystrophy (CMD) englobes several genetic diseases that cause muscle weakness from birth. As patients age, the disease becomes more severe and affects breathing, often leading to death before adulthood. Unfortunately, there […] June 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email